The effects of intravenously administered aminophylline on growth hormone (GH) secretion have been studied in sixteen normal subjects and four acromegalic patients. Intravenous infusion of theophylline ethylenediamine 480 mg over a 30 min period did not alter the blood glucose and serum GH levels in six normal subjects but raised the plasma FFA by 88 %. By contrast, in four acromegalic patients theophylline administration resulted in a fall of the serum GH levels by 17.6\p=n-\51.7 %, mean 36.5%. In ten normal subjects the infusion of the drug clearly blunted the GH response to insulin hypoglycaemia without modifying the decrease in blood glucose and plasma FFA induced by insulin: mean peak GH values decreased from 32.7 \ m=+-\3.39 to 21.4 \ m=+-\4.10 ng/ml (P < 0.025). These data seem to indicate that theophylline has an overall inhibiting effect on the hypothalamic-hypophyseal axis for GH secretion.
similarly, cAMP, its mono and dibutyryl derivatives and theophylline, an in¬ hibitor of cAMP phosphodiesterase, have been shown to stimulate GH release from pituitary tissue in vitro (Schofield 1967; Wilbur et al. 1968; Steiner et al. 1970; Hertelendy et al. 1971; Lockhart 8c Taylor 1971; Posternak et al. 1971; Pelletier et al. 1972) .
Little is known, however, about the role of cAMP in the hypothalamic secretion of GH-releasing factor and therefore on GH secretion in vivo.
In man, peripheral administration of aminophylline increases the intra¬ cellular concentration of cAMP, thus providing the opportunity of studying the influence of this nucleotide on the hypothalamic-hypophyseal axis for GH secretion.
In the present work, the effect of aminophylline on GH secretion was in¬ vestigated in a group of normal subjects and in four acromegalie patients.
MATERIAL AND METHODS
Sixteen normal subjects (7 males and 9 females, ranging in age 21-69 years, mean 35.9 years) and four acromegalie patients (2 males and 2 females, aged 35-57 years, mean 45.7 years) volunteered for this study, the experimental purpose of which was explained in detail so that a fully informed consent was obtained. The normal subjects were in-patients convalescing from minor diseases, and within 10°/o of the ideal body-weight, without a family history of diabetes or any clinical evidence of endo¬ crine and metabolic abnormalities.
Aminophylline (theophylline ethylenediamine) 480 mg was infused into six normal and four untreated acromegalie patients over a 30 min period: 240 mg was infused from 0 to 10 min and the remaining 240 mg during the following 20 min; blood samples were collected at -30, 0, 10, 20, 30, 45, 60, 90 and 120 min. In ten normal subjects, an insulin tolerance test (0.1 U crystalline insulin/kg body weight injected iv) was performed on two separate occasions, in a random order, with a five days interval: in one of the two tests, insulin injection was followed by the infusion of aminophylline as described above. The time of blood sampling was -30, 0, 20, 30, 45, 60, 90 1972 ). On the other hand, the increase in serum GH observed in the monkey and in man after peripheral infusion of cAMP may be non-specific due to the side effects accompanying cAMP administration (Gagliardino 8c In any event, the possibility that the effects of aminophylline on GH secre¬ tion observed in the present study are produced by mechanisms other than an increase in cAMP, cannot be ruled out; indeed, aminophylline increases the cerebral vascular resistance thus decreasing the brain flow (Wechsler et al. 1950 ).
In conclusion, our data seem to indicate that an increase in cerebral cAMP concentration has an inhibiting action on GH secretion in man. Further studies are needed, however, for a better understanding of the role of this nucleotide in the regulation of GH release.
